[Current pharmacotherapy of overactive bladder in neurological patients].
The literature data on the urgent neurological problem - overactive bladder (OAB) are summarized. The OAB prevalence, current conceptions on the physiology and pathophysiology of urination and pathogenetic mechanisms of OAB development are presented. Main groups of pharmacological agents used in OAB treatment are described. Special attention is drawn to rationale of using anticholinergic (antimuscarinic) drugs. The authors present the results of their own comparative analysis on the efficacy and tolerability of these drugs in treatment of patients with cerebral vascular diseases including the use of solifenacin succinate (VESIcare).
FGBU 'Nauchnyĭ tsentr nevrologii' RAMN, Moskva; Nauchno-issledovatel'skiĭ institut uronefrologii i reproduktivnogo zdorov'ia cheloveka, Moskva.
P G
PG
Shvarts
Nauchno-issledovatel'skiĭ institut uronefrologii i reproduktivnogo zdorov'ia cheloveka, Moskva; GBOU VPO 'Pervyĭ moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova', Moskva.
A Z
AZ
Vinarov
FGBU 'Nauchnyĭ tsentr nevrologii' RAMN, Moskva.
A S
AS
Kadykov
FGBU 'Nauchnyĭ tsentr nevrologii' RAMN, Moskva.
I V
IV
Borodulina
FGBU 'Nauchnyĭ tsentr nevrologii' RAMN, Moskva.
S V
SV
Popov
FGBU 'Nauchnyĭ tsentr nevrologii' RAMN, Moskva.
M A
MA
Kravchenko
D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D011812:Quinuclidines / Q000627:therapeutic use; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014554:Urination; D064804:Urological Agents / Q000627:therapeutic use*
D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D064804:Urological Agents; D000069464:Solifenacin Succinate